ALEJANDRO GIL: Open Payments
NPI 1417951963 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,243 in 48 payments from 14 companies in 2025. Trend: 2023 $2,793 · 2024 $2,844 · 2025 $2,243
Food & beverage: $2,243
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $482 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $480 |
| ABBVIE INC. | 6 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $249 |
| Lilly USA, LLC | 3 | $167 |
| Otsuka America Pharmaceutical, Inc. | 6 | $148 |
| Ardelyx, Inc. | 4 | $122 |
| Novo Nordisk Inc | 2 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
Products named: Kerendia, EVENITY, CAPLYTA, OTEZLA, REXULTI, QULIPTA, UBRELVY, IBSRELA.
Industry payments across CA — which companies pay providers there.
